Pharmacokinetics of Sulbactam/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem‐Resistant Acinetobacter baumannii Bacteremia: A Case Report
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70042 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Dan Ilges und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic Arizona, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Acute Kidney Injury, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Carbapenem‐resistant Acinetobacter baumannii (CRAB) are difficult‐to‐treat pathogens that primarily cause health care‐associated infections. Sulbactam/durlobactam (SUL/DUR) is a novel antibiotic combination that is uniquely formulated to target CRAB isolates. However, investigations of SUL/DUR's pharmacokinetics in obese patients are limited. Here, we report on the successful treatment of CRAB bacteremia in a patient with acute renal failure and severe obesity (weight 273 kg, body mass index 103 kg/m 2 ) with SUL/DUR and meropenem combination therapy. The patient had a calculated creatinine clearance of 25 mL/min and received therapy with intravenous SUL/DUR 1 g/1 g every 8 h over 3 h in combination with intravenous meropenem 500 mg every 8 h to complete 14 days of therapy. Pharmacokinetic analysis revealed target attainment with prolonged half‐life ( T 1/2 ) and volume of distribution (Vd) of 35.3 h and 81.3 L for sulbactam and 30.5 h and 169.1 L for durlobactam, respectively. Susceptibility testing using the broth disk elution test did not show synergy between SUL/DUR and meropenem. No adverse effects were observed, and the patient achieved clinical cure without recurrence of A. baumannii infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic Arizona, Phoenix, Arizona, USA.
- Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
- Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, Arizona, USA.
ORCID-Profile: Dan Ilges, Yakun Fu, Drew T Dickinson, John C Robinson, Lisa Speiser
Zitieren
APA
Ilges, D., Fu, Y., Dickinson, D. T., Robinson, J. C., Speiser, L., & Nicolau, D. P. (2025). Pharmacokinetics of Sulbactam/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem‐Resistant Acinetobacter baumannii Bacteremia: A Case Report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70042
Vancouver
Ilges D, Fu Y, Dickinson DT, Robinson JC, Speiser L, Nicolau DP. Pharmacokinetics of Sulbactam/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem‐Resistant Acinetobacter baumannii Bacteremia: A Case Report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70042
BibTeX
@article{Ilges2025,
author = {Ilges, Dan and Fu, Yakun and Dickinson, Drew T and Robinson, John C and Speiser, Lisa and Nicolau, David P},
title = {Pharmacokinetics of Sulbactam/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem‐Resistant Acinetobacter baumannii Bacteremia: A Case Report},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70042}
}
EUVIMED